Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression by Emanuel Severus et al.
OPINION Open Access
Mirroring everyday clinical practice in clinical trial
design: a new concept to improve the external
validity of randomized double-blind placebo-
controlled trials in the pharmacological treatment
of major depression
Emanuel Severus1,2*, Florian Seemüller2, Michael Berger2, Sandra Dittmann2, Michael Obermeier2, Andrea Pfennig1,
Michael Riedel2,3, Sophia Frangou4, Hans-Jürgen Möller2 and Michael Bauer1
Abstract
Background: Randomized, double-blind, placebo-controlled trials constitute the gold standard in clinical research
when testing the efficacy of new psychopharmacological interventions in the treatment of major depression.
However, the blinded use of placebo has been found to influence clinical trial outcomes and may bias patient
selection.
Discussion: To improve clinical trial design in major depression so as to reflect clinical practice more closely we
propose to present patients with a balanced view of the benefits of study participation irrespective of their
assignment to placebo or active treatment. In addition every participant should be given the option to finally
receive the active medication. A research agenda is outlined to evaluate the impact of the proposed changes on
the efficacy of the drug to be evaluated and on the demographic and clinical characteristics of the enrollment
fraction with regard to its representativeness of the eligible population.
Summary: We propose a list of measures to be taken to improve the external validity of double-blind, placebo-
controlled trials in major depression. The recommended changes to clinical trial design may also be relevant for
other psychiatric as well as medical disorders in which expectations regarding treatment outcome may affect the
outcome itself.
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Background
The treatment of patients with major depression
remains one of the major challenges in psychiatry in the
21st century [1-3]. There is a general consensus that
antidepressant medications are an essential component
of the treatment plan at any stage of the illness and par-
ticularly in severe cases [4,5].
In the era of evidence-based medicine, randomized,
double-blind, placebo-controlled, trials constitute the
gold standard for testing the efficacy of new pharmacolo-
gical interventions for major depression [6,7]. Their
unique strength derives from the fact that they allow
comparisons of a psychopharmacologically active medi-
cine to an identical looking ‘medicine’ which does not
contain any active ingredient (placebo). Randomization is
thought to ensure unbiased allocation of patients to each
treatment arm while blinding both patients and investiga-
tors to treatment allocation safeguards against biased
reporting of potential benefits or adverse effects [8].
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During the last few years however it has become
increasingly evident that the very strength of this type of
trial, that is, the blinded use of placebo, may itself influ-
ence antidepressant and placebo response and remission
rates [9,10] and consequently clinical trial outcome [11].
As neither randomization nor double-blinded placebo
administration are part of normal clinical practice the
external validity of results obtained from randomized,
double-blind, placebo-controlled trials may not repre-
sent real life outcomes [12,13]. Some of these limitations
are introduced by the stringent eligibility criteria of clin-
ical trials that routinely exclude patients with complex
presentations [14,15]. In addition, the acceptability of
eligible patients to be randomized to the placebo arm is
considered to be highly variable thus further limiting
the number of participants to enroll in such studies
[16]. In many cases differences in outcome-relevant
demographic and clinical characteristics of eligible
patients that were enrolled (enrollment fraction) versus
those that refused are not described in detail, which
makes it difficult to draw reliable conclusions regarding
the external validity of the trial [17]. Therefore, a new
study design is needed which reconciles the needs of
clinical research meeting highest methodological stan-
dards (double-blinding, placebo-control) and at the
same time preserves the external validity of the findings
derived from these studies [18].
Discussion
While clinical trials in major depression focus on the
antidepressant efficacy of medications, clinical care has a
wider remit and is concerned with the overall treatment
of individual patients suffering from this disorder. In the
context of clinical care the medication offered is already
approved and the choice of the specific antidepressant
does not happen in a randomized fashion but through a
process of shared decision making between the treating
physician (primary care doctor, psychiatrist) and the
patient [19-21]. During this process patients are informed
of the potential consequences of treatment choices
including expected benefits. The combination of using an
approved antidepressant and the patients’ active partici-
pation in treatment choices creates positive expectations
regarding the effectiveness of the treatment agreed upon
and may positively affect the overall outcome [22]. In
contrast, in any randomized double-blind placebo-con-
trolled trial, and particularly in Phase III trials, the expec-
tation of a positive outcome is lessened by the knowledge
that participants may be randomized to the placebo arm
[9-11,23-26]. However, in the absence of alternatives,
only those drugs proven efficacious in the aforemen-
tioned double-blind, placebo-controlled randomized
trials have been approved for use for the treatment of
major depression. To improve external validity of
randomized, double-blind, placebo-controlled trials in
major depression we propose to introduce two core fea-
tures of everyday clinical practice, namely shared decision
making and availability of the active medication to all
participants, into randomized, double-blind, placebo-con-
trolled trials and to study the effects of this intervention
on study outcome and recruitment.
Mirroring clinical practice in double-blind, placebo-
controlled trials
The introduction of the core features outlined above will
be achieved in a number of steps:
1) Active medication for all study participants: At the
end of late phase III clinical trials study participants
could be offered the option of receiving the active
medication or to remain on the study medication if it
had been efficacious and well tolerated. The duration
of this non-randomized phase could vary according to
clinical need and patient preference.
2) Detailed explanation of potential benefits: Placebo is
often referred to as an ‘inert and deceptive interven-
tion intended to please or placate the patient but with-
out any potential to produce meaningful therapeutic
results’ [27]. While not explicitly stated in the
informed consent form (ICF) patients may conse-
quently conclude that only if they are assigned to the
active medication will they have a reasonable chance
to improve regarding their depression. As this is not
true we propose to reconceptualize what a placebo -
and being randomized to the placebo arm - constitu-
tes. This would involve explaining to study participants
that improvement in their depressive symptoms may
occur spontaneously while on the placebo arm, in
which case they may have been spared unnecessary
medication [25]. Additionally it should be emphasized
that study participation is likely to result in increased
and more regular contact with clinicians and closer
monitoring of their symptoms which can be beneficial
in its own right [28].
The combination of these features mirrors clinical prac-
tice and redresses patients’ fears of a negative outcome fol-
lowing study participation [22]. An appropriate tool to
convey the above mentioned information seems to be the
informed consent form [29]. Traditional informed consent
forms currently state that ‘A placebo or inactive medicine
looks like real medicine but it is not. It is a dummy or pre-
tend medicine. It has no effect on a person because it has
no real medicine in it’ (World Health Organization
Research Ethics Review Committee). In contrast to this
statement we propose the following (or similar) wording
for a double-blind placebo-controlled randomized trial in
major depression:
Severus et al. BMC Medicine 2012, 10:67
http://www.biomedcentral.com/1741-7015/10/67
Page 2 of 5
‘The goal of this trial is to find out whether patients
receiving drug ‘X’ will have an additional benefit com-
pared to those receiving a placebo. A placebo or inactive
medicine looks like real medicine, but contrary to a real
medicine, it does not contain any substance believed to
influence brain mechanisms relevant to depression. How-
ever, patients receiving placebo in clinical trials for
depression often report significant improvements in their
symptoms. There may be several reasons for this. Firstly,
depressive symptoms are known to improve even without
treatment as part of the natural course of the illness. Sec-
ond, having frequent and regular discussion about your
feelings and progress with the study clinicians may be
therapeutic in itself. Third, being positive about getting
better during the clinical trial may actually contribute to
improving your symptoms [22,30]. Therefore, regardless
of the type of medicine you might receive (X or placebo)
you may benefit from participating in this trial. Finally, at
the end of the study you will be offered the option of
receiving the active medication or remaining on the
study medication. You can then decide together with
your doctor what would be the appropriate next steps. If
the study medication had been of benefit to you, you may
want to continue on this medicine. In contrast, if you
and your study doctor feel that you had not responded
satisfactorily to the study medication, you may want to
vote for the option of being given X if clinically
appropriate’.
Research agenda
In order to test the impact of shared decision making and
of study drug availability to all participants we propose to
start with a number of Phase IV trials. In this agenda we
will refer to a study design incorporating these proposed
changes as an ‘enhanced randomized controlled trial
(RCT)’. This agenda should focus on comparing the anti-
depressant efficacy of study drug ‘X’ when evaluated
using a traditional double-blind RCT versus the proposed
enhanced RCT design. The evaluation will consist of
comparisons of the effect size of placebo-active treatment
arms differences on depressive symptoms and on out-
come-relevant demographic and clinical characteristics of
enrolled patients. This would then allow an estimation of
the representativeness of the enrolled patients compared
to all patients in the eligible target patient population.
The set of trials we propose to conduct consists of
two steps:
In the first step potentially eligible patients suffering
from a major depressive episode in the context of a
major depressive disorder will be asked about their will-
ingness, in general, to participate in clinical trials to eval-
uate different study designs on antidepressant efficacy.
They will be given a first informed consent form (ICF#1)
which will outline the general purpose of the trial but
will not include details regarding study design. If patients
are interested they will be asked to sign ICF#1. By doing
so they give permission to study clinicians to access and
analyze outcome relevant demographic and illness-
related variables and check their eligibility for inclusion
in clinical trials. This may also involve drawing blood for
laboratory tests. Those signing ICF#1, and who fulfill
eligibility criteria, will then be randomized to one of the
following two treatment trial set ups (not treatment
arms):
1) traditional double-blind, randomized, placebo-con-
trolled eight-week trial, including a traditional informed
consent form, no option for extension period; or
2) enhanced double-blind, randomized, placebo-con-
trolled eight-week trial, including the novel informed
consent form outlined above, option for extension
period.
The two treatment trials will be conducted by inde-
pendent research teams who will be unaware that the
two trial designs will be compared. Each clinical trial
team will approach patients randomized to their study
design (traditional or enhanced) and will ask them for
their consent to participate. The wording of the ICF#2
will differ between the two trial designs. Patients
approached to participate in the traditional trial will be
presented with the traditional version of the ICF#2
while patients approached to participate in the enhanced
trial will be given the new proposed ICF#2 outlined
above.
At study completion the traditional and enhanced
designs will be compared in terms of:
1) Efficacy, by comparing the outcomes of the two
trial designs based on the effect size symptom score
improvement, number of responders, number of
patients in remission, number of patients withdraw-
ing, and Number Needed to Treat;
2) Tolerability, by comparing the outcomes of the
two trial designs based on number and type of
reported adverse events; and
3) Representativeness of study participants, by com-
paring outcome-relevant demographic and clinical
characteristics of enrolled patients in each design
(enrollment fraction) to the respective eligible target
clinical population.
Comparisons between the two study designs can be
straightforward and performed using ordinary linear mod-
els with treatment success being explained by study arm,
study design and their interaction. As the goal is to assess
study designs rather than specific drugs, the active medica-
tion to begin with, in both the traditional and enhanced
clinical trials outlined, will be sertraline which has already
been approved for the treatment of depressive disorder
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and is thought to have a balanced profile of efficacy and
tolerability [31,32]. For the purpose of this project, the
research teams on both clinical trial designs will be blind
to the active drug so as not to influence their evaluation.
Equally patients will be told in the ICF#2 that they will be
randomized ‘either to placebo or to a drug thought to be
helpful in depression’. In addition precise information will
be provided about potential side effects which will be reas-
suring to all study participants. In this way we will be able
to use existing literature on sertraline for power calcula-
tions for the traditional and enhanced clinical trials exam-
ined here. Additionally, this availability of multiple
previous sources of information about sertraline will allow
us to discuss findings from this project in the context of
the wider literature.
Summary
In the era of evidence-based medicine it is paramount
that we produce clinically relevant scientific evidence for
the pharmacological treatment of patients with major
depression. We therefore propose to enhance double-
blind, placebo-controlled trials in such a way as to
reflect clinical practice more closely. This could be
achieved by adding extensions, thus offering every
patient the possibility of receiving active treatment and
formally integrating the process of shared decision mak-
ing while obtaining informed consent. The proposed
changes in the process of informed consent focus on a
balanced presentation of evidence regarding the benefit
of study participation irrespective of whether patients
are assigned to active or placebo treatment. In order to
evaluate the impact of the study designs on the efficacy
and enrollment fraction of an intervention we further
outlined a research agenda involving direct comparison
of traditional and enhanced trial designs. While we feel
that our approach represents an important step towards
a more comprehensive assessment of the efficacy and
external validity of the treatment options available,
further research is needed in this area to improve the
clinical care of patients suffering from this complex and
often severely debilitating psychiatric illness [33]. Finally,
while our proposal primarily targets major depression
its central idea may also be relevant for other psychiatric
disorders as well as medical disorders such as asthma, in
which expectations regarding treatment outcome may
affect the outcome itself [34,35].
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